Astellas Pharma Inc - ESG Rating & Company Profile powered by AI
This page includes a questions and answers section for Astellas Pharma Inc. Scroll down to the end of the webpage for potential risks for Astellas Pharma Inc based on industry, geography and marketcap. The page is a zero-cost Sustainability assessment covering Astellas Pharma Inc.
Astellas Pharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.0; made up of an environmental score of 4.0, social score of 6.0 and governance score of 8.0.
6.0
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 483 | Wakamoto Pharmaceutical Co Ltd | 6.1 | High |
| 483 | aTyr Pharma Inc | 6.1 | High |
| 498 | Astellas Pharma Inc | 6.0 | High |
| 498 | Cann Group Ltd | 6.0 | High |
| 498 | Biosynex SA | 6.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Astellas Pharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Astellas Pharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Astellas Pharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Astellas Pharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Astellas Pharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Astellas Pharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Astellas Pharma Inc offer flexible work?
Sign up for free to unlockDoes Astellas Pharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Astellas Pharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Astellas Pharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Astellas Pharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Astellas Pharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Astellas Pharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Astellas Pharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Astellas Pharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Astellas Pharma Inc disclose water use targets?
Sign up for free to unlockDoes Astellas Pharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Astellas Pharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Astellas Pharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Astellas Pharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Astellas Pharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Astellas Pharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Astellas Pharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Astellas Pharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Astellas Pharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Astellas Pharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Astellas Pharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Astellas Pharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Astellas Pharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Astellas Pharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Astellas Pharma Inc disclose its waste policy?
Sign up for free to unlockDoes Astellas Pharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Astellas Pharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Astellas Pharma Inc disclose energy use targets?
Sign up for free to unlockDoes Astellas Pharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Astellas Pharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Astellas Pharma Inc
These potential risks are based on the size, segment and geographies of the company.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.